FDA Brief

Warning letters Drugs

FDA warning letter to

Winder Laboratories, LLC

High riskIssued Jan 7Posted Jan 13Center for Drug Evaluation and Research (CDER)

FDA warns Winder Laboratories of adulterated prescription drugs due to cleaning and facility failures.

What happened

FDA inspected Winder Laboratories' drug manufacturing facility in Winder, Georgia, from July 14 to August 5, 2025. FDA observed equipment with drug residue and oxidized metal that had been released as clean, a nonfunctioning and unqualified metal detector, a metal screw in a sealed bottle, and facility defects such as wall gaps and an unknown brown-yellow material. FDA also said similar CGMP violations were cited in prior inspections.

What FDA found

  1. FDA found drug residue and oxidized metal on manufacturing equipment that the quality unit had documented as clean.

    21 CFR 211.67(a) and (b)
  2. FDA found the metal detector nonfunctioning and not qualified, and a metal screw in a sealed bottle.

    21 CFR 211.67(a) and (b)
  3. FDA observed wall gaps, unknown brown-yellow material, a taped ceiling vent, and unfinished walls in manufacturing areas.

    21 CFR 211.58
  4. FDA said the firm's quality systems are inadequate.

    21 CFR parts 210 and 211
  5. FDA cited similar CGMP violations at prior inspections in 2018, 2022, and 2023.

  6. FDA said the drug products are adulterated because manufacturing did not meet CGMP.

    section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B)

What FDA wants

FDA asks Winder to respond in writing within 15 working days with corrective actions and supporting documents, including independent cleaning assessments, CAPA plans, cleaning validation improvements, equipment qualification, and evidence of facility repairs. FDA also recommends engaging a qualified CGMP consultant.

Who should pay attention

  • brands that buy prescription tablets from this contract manufacturer
  • pharmacies and patients receiving affected lots
  • companies relying on Winder's cleaning and metal-detection controls

This is a summary. Read the original letter on fda.gov.

Winder Laboratories, LLC's FDA history

Recalls in the last 12 months

Mar 25 Class III Winder Laboratories, LLC
Food
Multivitamin with Fluoride Chewable Tablets Grape Flavor Rx NDC 75826-169-10 0.25 mg 100 TABLETS UPC 3 15826 16910 2; NDC 75826-171-10 1mg 100 TABLETS UPC 3 15826 17110 5 Manufactured by: WINDER LABORATORIES LLC Winder, …
Subpotent. During an FDA inspection it was discovered that the product was subpotent for Vitamin D.
Dec 17, 2025 Class III Winder Laboratories, LLC
Drug
Morphine Sulfate Oral Solution 100 mg / 5 mL (20 mg* / mL), 30 mL, Rx Only, For Oral Use Only, Manufactured By: /winder Laboratories, LLC, Winder, GA 30680. NDC: 75826-131-01
Correct Labeled Product Mispack-Size stated on carton label did not match the size of the bottle in the carton.

Full company page

Similar letters to other companies

  1. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk
  2. Silgan Dispensing Systems

    Silgan Unicep Packaging was cited for manufacturing quality failures and unapproved new drugs after invalidated microbial tests and a fungal recall.

    High risk
  3. Bentley Laboratories LLC

    Bentley Laboratories LLC was cited for CGMP violations and for marketing unapproved acne drugs.

    High risk
  4. Stream2Sea, LLC

    FDA found Stream2Sea, an OTC drug maker in Bowling Green, Florida, released drug batches without finished-product testing, raw material identity testing, or validated cleaning.

    Medium